An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of one fixed 100 mg dose of saredutant in patients with major depressive disorder.

Trial Profile

An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of one fixed 100 mg dose of saredutant in patients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Saredutant (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Dec 2008 Actual patient number (465) added as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Actual end date changed from Aug 2006 to Dec 2006 as reported by Clinicaltrials.gov.
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top